DTB: Vol 19, No 4. August - October 2011

Content tools

Share it

Biotechnology drugs and cancer. All that glitters is not gold

Some biotechnology drugs have shown to be useful in the treatment of cancer patients. However, the majority present questionable efficacy, considerable adverse effects and are costly. It is convenient to demonstrate greater scientific rigor when approving or withdrawing these drugs. The public health services should consider selective financing of these drugs in terms of treatment benefits.

Download pdf

Author:

Juan Erviti. Drug Information Unit. Navarre Regional Health Service. Spain

Link to the podcast and video (Spanish)

Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)

First name, middle initial and last name *

Email *

Current position or occupation *

Place of work *

Suggestions/Comments *

navarra.es

DTB: Vol 19, No 4. August - October 2011

Biotechnology drugs and cancer. All that glitters is not gold